Table 3.
Virological failure (VL > 1000 copies/ml) according to age category, months on ART and geographic origin in perinatally HIV-1-infected children and adolescents
Virological failure rates (>1000 copies/ml), N/N (%) | |||
---|---|---|---|
|
|||
Characteristics | Total | Female | Male |
Age categories (years) | |||
<5 | 9/20 (45.0%) | 5/7 (57.1%) | 4/13 (30.8%) |
5 to 10 | 68/127 (53.6%) | 42/69 (60.9%) | 26/58 (44.8%) |
11 to 14 | 47/98 (48.0%) | 20/50 (40.0%) | 27/48 (56.3%) |
15 to 19 | 23/38 (60.5%) | 11/16 (68.8%) | 11/22 (50.0%) |
Total | 147/283 (51.9%) | 78/142 (54.9%) | 68/141 (48.2%) |
Months on ART | |||
12 to 24 | 21/46 (45.6%) | 10/24 (41.7%) | 11/22 (50.0%) |
25 to 36 | 34/61 (55.7%) | 21/34 (61.8%) | 13/27 (48.2%) |
37 to 48 | 17/35 (48.6%) | 12/20 (60.0%) | 5/15 (33.3%) |
49 to 60 | 24/46 (52.2%) | 7/18 (38.9%) | 17/28 (60.7%) |
61 to 72 | 15/32 (46.9%) | 9/17 (53.0%) | 6/15 (40.0%) |
>72 | 35/63 (55.6%) | 19/29 (65.5%) | 16/34 (47.1%) |
Geographic origin | |||
Urban (Lomé, capital city) | 93/189 (49.2%) | 46/90 (51.1%) | 47/99 (47.5%) |
Semi-rural | 53/94 (56.4%) | 32/52 (61.5%) | 21/42 (50.0%) |
ART, antiretroviral therapy; VL, viral load.